Novavax’s Covid-19 vaccine wins backing of CDC advisory panel
An expert panel that advises the Centers for Disease Control and Prevention on vaccine policy voted Tuesday to recommend use of Novavax’s Covid-19 vaccine — an achievement a long time in the making for the Gaithersburg, Md.-based company.
The Advisory Committee on Immunization Practices voted 12 to 0 to recommend the vaccine, with several members expressing hope that the vaccine’s makeup may persuade some people who have been reluctant to get vaccinated against Covid to finally roll up a sleeve. The vaccine is a recombinant protein product, developed with the same kind of approach that is used for a brand of flu vaccine. Some people who have refused Covid vaccines have expressed hesitancy over the messenger RNA vaccines produced by Moderna and the Pfizer and BioNTech partnership.
Read Original Article: Novavax’s Covid-19 vaccine wins backing of CDC advisory panel »
